(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 22.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Vericel's revenue in 2024 is $214,520,000.On average, 3 Wall Street analysts forecast VCEL's revenue for 2024 to be $11,803,328,209, with the lowest VCEL revenue forecast at $11,753,023,249, and the highest VCEL revenue forecast at $11,880,011,403. On average, 3 Wall Street analysts forecast VCEL's revenue for 2025 to be $15,123,994,871, with the lowest VCEL revenue forecast at $14,690,911,335, and the highest VCEL revenue forecast at $15,501,380,128.
In 2026, VCEL is forecast to generate $19,198,549,504 in revenue, with the lowest revenue forecast at $18,081,347,937 and the highest revenue forecast at $20,394,591,593.